WallStSmart
LTRN

Lantern Pharma Inc

NASDAQ: LTRN · HEALTHCARE · BIOTECHNOLOGY

$3.13
-9.09% today

Updated 2026-06-03

Market cap
$45.80M
P/E ratio
P/S ratio
EPS (TTM)
$-1.45
Dividend yield
52W range
$1 – $6
Volume
0.8M

Lantern Pharma Inc (LTRN) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20182019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$-2544.00$1627.00$3388.00$97421.00$154681.00$174843.00$190493.00$17280.00
Gross profit$2544.00$-1627.00$-3388.00$-97421.00$-154681.00$-174843.00$-190493.00$-17280.00
Gross margin
R&D$572095.00$953185.00$2.24M$7.57M$8.60M$11.89M$16.13M$11.51M
SG&A$1.15M$1.48M$3.66M$5.02M$5.83M$5.98M$6.09M$6.46M
Operating income$-1.73M$-2.43M$-5.91M$-12.59M$-14.43M$-17.88M$-22.22M$-17.98M
Operating margin
EBITDA$-1.73M$-2.43M$-5.90M$-12.58M$-14.42M$-15.79M$-22.20M$-17.96M
EBITDA margin
EBIT$-1.73M$-2.43M$-5.91M$-12.59M$-14.43M$-15.96M$-22.22M$-17.98M
Interest expense$0.00$0.00$0.00$221718.00$204355.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-1.73M$-2.43M$-5.91M$-12.36M$-14.26M$-15.96M$-20.78M$-17.12M
Net income growth (YoY)-40.6%-143.3%-109.3%-15.3%-11.9%-30.2%+17.6%
Profit margin

Frequently asked questions

How much free cash flow does LTRN generate?

LTRN produced $-15.68M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is LTRN's balance sheet healthy?

LTRN holds $4.42B in cash and equivalents against — in long-term debt, on $6.53B of shareholder equity. That debt is best read against the cash flow the business throws off each year.